Recombinant factor VIIa for the prophylaxis of perioperative hemorrhage in a patient with congenital factor XI deficiency undergoing brain tumor neurosurgery.
The authors report on the first successful use of recombinant activated factor VII for the prophylaxis of bleeding during brain tumor neurosurgery in a patient suffering from inherited factor XI deficiency. Using the agent, surgery was performed without any bleeding complications. In this setting, off-label use of recombinant activated factor VII appears to be a promising alternative for patients suffering from this rare hemostatic defect with hitherto limited therapeutic options.
Sucker
Christoph
C
Department of Hemostasis and Transfusion Medicine, Heinrich Heine University Medical Center, Moorenstrasse 5, Dusseldorf, Germany.
Sabel
Michael
M
Stummer
Walter
W
Zotz
Rainer B
RB
Scharf
Ruediger E
RE
Gerhardt
Andrea
A
D016063:Blood Loss, Surgical / Q000517:prevention & control*; D001932:Brain Neoplasms / Q000601:surgery*; D015942:Factor VIIa / Q000627:therapeutic use*; D005173:Factor XI Deficiency / Q000150:complications; D006801:Humans; D008297:Male; D008875:Middle Aged; D011994:Recombinant Proteins / Q000627:therapeutic use
D011994:Recombinant Proteins; D015942:Factor VIIa